Navigation Links
Anthera Pharmaceuticals to Present at Annual Jefferies Healthcare Conference
Date:5/31/2013

HAYWARD, Calif., May 31, 2013 /PRNewswire/ -- Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH), a biopharmaceutical company focused on developing and commercializing products to treat autoimmune diseases, announced today that Paul F. Truex , President and Chief Executive Officer, and Dr. Colin Hislop , Senior Vice President and Chief Medical Officer, will present a corporate update at the 2013 Annual Jefferies Global Healthcare Conference.

Anthera will present on at 1:30PM ET, June 6th in Ballroom 1 of the Grand Hyatt Hotel in New York City.

About Blisibimod and PEARL-SC

Anthera is developing blisibimod, a selective inhibitor of B-cell activating factor (BAFF), to explore its clinical utility in various autoimmune diseases including systemic lupus erythematosus (SLE) and IgA nephropathy. Blisibimod is a novel fusion protein, or peptibody, and is distinct from an antibody. Anthera owns worldwide rights to blisibimod in all potential indications. BAFF, also known as BLyS (B lymphocyte stimulator), is a tumor necrosis family member and is critical to the development, maintenance and survival of B-cells. B-cells represent a critical component of human immune response to infection and other pathogens.  However, abnormal elevations of B-cells and BAFF may lead to an overactive immune response which may damage normal healthy tissues and organ systems. Multiple clinical studies with BAFF antagonists have reported the potential benefit of BAFF inhibitors in treating patients with lupus and rheumatoid arthritis.

In April 2012, Anthera completed the PEARL-SC Phase 2b clinical study to evaluate the efficacy and safety of subcutaneous blisibimod in patients with active and seropositive lupus. In June and July of 2012 Anthera announced results fro
'/>"/>

SOURCE Anthera Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Anthera Pharmaceuticals Reports 2013 First Quarter Financial Results
2. Anthera Pharmaceuticals Announces Additional Data from Phase 2b PEARL-SC Blisibimod Study
3. Anthera Refinances Existing Debt with New $20 Million Credit Facility and Secures $18.5 Million Committed Equity Financing Facility
4. Anthera Initiates CHABLIS-SC1 Phase 3 Clinical Study in Lupus with Blisibimod
5. Anthera Announces Data from the Phase 2b PEARL-SC Study Will Be Presented at the 10th International Congress on Systemic Lupus Erythematosus
6. Anthera Pharmaceuticals to Present at the 2013 Leerink Global Healthcare Conference
7. Anthera Pharmaceuticals Announces Departure of Georgina Kilfoil
8. Anthera Pharmaceuticals Announces Completion of Public Offering of Common Stock
9. Anthera Announces Data from the Phase 2b PEARL-SC Study Presented at the 2012 Asian Lupus Summit
10. Anthera Pharmaceuticals to Present at the Piper Jaffray Health Care Conference
11. Anthera Announces Additional Data from the Phase 2b PEARL-SC Presented at the ACR/ARHP 2012 Annual Scientific Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... , Sept. 2, 2014 Donald ... been granted US Pat.# 8,823,512 for a Wearable Biosensor, ... his large portfolio in this field.  Mr. Spector holds ... The announcement was made today by New York ... years into a powerhouse of world-class intellectual properties.  New ...
(Date:9/2/2014)... N.C. , Sept. 2, 2014  Edison ... announced a partnership with the American Association for ... association of respiratory care specialists. Edison Nation Medical, ... and small business to commercialize their innovation ideas, ... association,s community of more than 50,000 respiratory therapists ...
(Date:9/2/2014)... DALLAS , Sept. 2, 2014 /PRNewswire-iReach/ -- ... driven by universal healthcare coverage and good access ... elderly population and its associated disease burden, well-defined ... the introduction of a new manufacturing policy will ... future. However, a focus on generic substitution and ...
Breaking Medicine Technology:Wearable Biosensor Patent, the Grandfather of Wearable Biosensor Transmission Patents, Granted to Donald Spector, One of the Most Prolific Living Inventors in the World 2Wearable Biosensor Patent, the Grandfather of Wearable Biosensor Transmission Patents, Granted to Donald Spector, One of the Most Prolific Living Inventors in the World 3Wearable Biosensor Patent, the Grandfather of Wearable Biosensor Transmission Patents, Granted to Donald Spector, One of the Most Prolific Living Inventors in the World 4Wearable Biosensor Patent, the Grandfather of Wearable Biosensor Transmission Patents, Granted to Donald Spector, One of the Most Prolific Living Inventors in the World 5Edison Nation Medical and AARC Team Up To Promote Innovation in Respiratory Care 2Edison Nation Medical and AARC Team Up To Promote Innovation in Respiratory Care 3Australia Medical Devices Market worth $10.4 billion by 2020 Says a New Report Available at MarketOptimizer.org 2Australia Medical Devices Market worth $10.4 billion by 2020 Says a New Report Available at MarketOptimizer.org 3Australia Medical Devices Market worth $10.4 billion by 2020 Says a New Report Available at MarketOptimizer.org 4Australia Medical Devices Market worth $10.4 billion by 2020 Says a New Report Available at MarketOptimizer.org 5
... MedShape Solutions, Inc., the industry leader in innovative ... developed new, larger sizes of its ExoShape CL, ... simplifies and improves soft tissue graft fixation during ... comes after MedShape received the U.S. Food and ...
... Neuralstem, Inc. (NYSE Amex: CUR ) announced that ... the ongoing Phase Ia trial to test the safety of ... testing the drug in healthy volunteers for safety and tolerability. ... that stimulates new neuron growth in the hippocampus, an area ...
Cached Medicine Technology:MedShape Solutions, Inc. Announces Extension of ExoShape™ Product Line in Response to Surgeon Demand 2Neuralstem Updates NSI-189 Major Depression Trial 2Neuralstem Updates NSI-189 Major Depression Trial 3
(Date:9/2/2014)... in California, the percentage undergoing a double mastectomy increased ... not associated with a lower risk of death than ... the September 3 issue of JAMA . The ... one breast was associated with a higher risk of ... , Randomized trials have demonstrated similar survival for patients ...
(Date:9/2/2014)... cancer cells can lay the groundwork for their own ... vessels to send out tumor-welcoming signals, according to a ... the Sept. 2 issue of Nature Communications , ... increased levels of so-called signaling molecules released by breast ... in the lungs and lymph nodes to produce proteins ...
(Date:9/2/2014)... Medex Analytic Services is delighted to ... Coral Springs, Fla. due to their greater than forecasted ... for the 2014 year by distinguishing Medex in the ... a higher level of service and professionalism in the ... the industry has responded.” , The location of the ...
(Date:9/2/2014)... (PRWEB) September 03, 2014 Operators in ... to millions of people annually, arranging care and counsel ... and private enterprises are expected to derive $39.4 billion ... donations and private income. Over the five years through ... annualised rate of 6.6%, including growth of 4.1% in ...
(Date:9/2/2014)... new studies further confirm the health benefits of breast-feeding. ... a lower risk of ear, throat and sinus infections ... similar trend when it comes to allergies. The ... immediate newborn period," said Dr. Jennifer Wu, an obstetrician-gynecologist ... was not involved in the new studies. The ...
Breaking Medicine News(10 mins):Health News:Increase seen in use of double mastectomy 2Health News:Increase seen in use of double mastectomy 3Health News:‘Prepped’ by tumor cells, lymphatic cells encourage breast cancer cells to spread 2Health News:Medex Analytic Services Announces New Location for Corporate Headquarters 2Health News:Community Services in Australia Industry Market Research Report Now Updated by IBISWorld 2Health News:Community Services in Australia Industry Market Research Report Now Updated by IBISWorld 3Health News:More Evidence Breast-Feeding Lowers Child's Risk of Infections, Allergies 2
... of "color-coded" laboratory mice are providing researchers with a ... and monitor the cellular immune responses of transplanted tissue ... in the June issue of Nature Medicine , ... are a key consideration in developing strategies to improve ...
... release is available in Spanish . , ... , from the Department of Physiology of the University ... Castillo Garzn . To carry out this project, the researcher ... and Assessment of Nutritional Status of Spanish Adolescents) and HELENA ...
... ... Cancer joins Cyberknife of Long Island , ... (PRWEB) May 27, 2010 -- Cyberknife of Long Island treats tumors ... Accuray offers unprecedented capabilities and renewed hope to prostate cancer patients. Cyberknife ...
... sex, still urged, experts say, , THURSDAY, May 27 (HealthDay ... for transmitting the virus to their partners by 90 percent ... Antiretroviral drug therapy helps reduce HIV levels in the infected ... to others. The drugs are commonly taken in the United ...
... in end-stage cardiac patients has a significantly lower risk for ... researchers at Henry Ford Hospital in Detroit. Known as ... HeartMate ,is much smaller than the first and uses a ... itself, to continually push blood through the body. Its predecessor ...
... ... no longer have access to per incident technical support services , ... (PRWEB) May 27, 2010 -- In a recent announcement ... Avaya maintenance agreement will no longer have access to per incident technical support services which ...
Cached Medicine News:Health News:Color-coded tracking method helps scientists analyze outcomes of newly transplanted tissue 2Health News:Color-coded tracking method helps scientists analyze outcomes of newly transplanted tissue 3Health News:Researchers validate a new test for assessing children's and teenagers' fitness to prevent morbidity 2Health News:Cyberknife of Long Island Destroys Prostate Cancer Non-Invasively Using Radiosurgery 2Health News:Cyberknife of Long Island Destroys Prostate Cancer Non-Invasively Using Radiosurgery 3Health News:Anti-HIV Drugs May Help Prevent Spread of Virus 2Health News:Henry Ford Hospital study: Fewer infections with new heart-pump implant 2Health News:Avaya Announces End of Support to Non Maintenance Customers 2
Livewire TC steerable ablation catheters are designed for the RF ablation of arrhythmias. They are available in a variety of curves and configurations, including bi-directional catheters for added fl...
Trilogy Pacemakers incorporates the clinically proven Omniscence™ accelerometer sensor with it's automatic alogorithms. The Trilogy family of pacemakers feature an array of products for bradyar...
... The Integrity ADx ... the world's smallest dual-chamber ... advanced pacemaker technology, including ... algorithm, the first U.S. ...
... Frontier II device is designed ... moderate to severe heart failure ... in patients who are symptomatic ... and who have prolonged QRS ...
Medicine Products: